Recent Finacing
Recent Raise
TKG Therapeutics develops miRNA-triggered hairpin nucleic‑acid therapeutics that assemble into STING/cGAS-activating structures for cancer-selective innate immune activation and is advancing formulation, nonclinical studies, and nucleic‑acid synthesizer R&D.
Focus Areas
Recent Investors
Funding round
Investors